Agenus Inc. has announced the appointment of Dr. José Iglesias as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for the company's immuno-oncology programs, including the development and early-access rollout of botensilimab and balstilimab for patients with microsatellite-stable colorectal cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251118089134) on November 18, 2025, and is solely responsible for the information contained therein.